Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Capricor Therapeutics Enters $1.5 Billion Partnership with Nippon Shinyaku for Deramiocel Commercialization.
Jan 10, 2026•5 months ago
Contract Type
partnership
San DiegoBiotechnologyTherapeuticsDescription
Capricor Therapeutics has entered into a significant commercialization and distribution partnership with Nippon Shinyaku covering the U.S., Japan, and Europe. This partnership follows the successful Phase 3 trial of its drug deramiocel, with potential milestones amounting to $1.5 billion.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months